The Administrative Core will provide for the administration of the Lymphoma SPORE, including administrative and budget support for all SPORE investigators. The Administrative Core directly supports management of SPORE projects, cores, and funds. Core A leverages existing institutional resources and infrastructure such as research regulatory committees, clinical trial data collection and management, clinical trial budgeting, IND development, technology licensing, and grants management. The Core will coordinate 1) monthly SPORE meetings and seminars, 2) quarterly research meetings, lectures, and symposia, 3) the annual SPORE retreat, 4) meetings of the Executive Committee and the Internal and External Advisory Boards, and 5) participation in NCI-sponsored SPORE meetings. This Core is involved with preparing and submitting annual progress reports and making decisions regarding the selection and support of the best and most promising projects. Integration and communication between the SPORE, the Department of Hematology and Hematopoietic Stem Cell Transplantation, and the Cancer Center Support (Core) Grant will be promoted. Importantly, the Administrative Core will be responsible for the oversight of the Developmental Research and Career Development Programs in the Lymphoma SPORE. Finally, the Core will also promote patient interests and equitable access to treatment on SPORE studies by working with a patient advocate to ensure that SPORE clinical studies are patient-centered, and by facilitating recruitment of minorities and underserved populations to SPORE clinical studies. Through performance of these objectives, the Administrative Core will ensure smooth functioning of the SPORE to maximize our efficiency, conserve resources, and expedite scientific progress and achievement.

Public Health Relevance

The Administrative Core is responsible for the administrative and budget support for all SPORE investigators. This Core coordinates meetings and facilitates the selection and support of the most promising projects. Therefore, it is ensured that resources are best spent towards developing new breakthroughs that may benefit patients in need of novel treatments.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA107399-11A1
Application #
9418459
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
11
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Herrmann, Andreas; Lahtz, Christoph; Nagao, Toshikage et al. (2017) CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. Cancer Res 77:5118-5128
Herrera, Alex F; Mei, Matthew; Low, Lawrence et al. (2017) Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. J Clin Oncol 35:24-31
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Herrera, Alex F; Armand, Philippe (2017) Minimal Residual Disease Assessment in Lymphoma: Methods and Applications. J Clin Oncol 35:3877-3887
Won, Haejung; Moreira, Dayson; Gao, Chan et al. (2017) TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs. J Leukoc Biol 102:423-436
Gibson, Christopher J; Lindsley, R Coleman; Tchekmedyian, Vatche et al. (2017) Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol 35:1598-1605
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2017) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant :
Urak, Ryan; Walter, Miriam; Lim, Laura et al. (2017) Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy. J Immunother Cancer 5:26
Zhang, Chunyan; Xin, Hong; Zhang, Wang et al. (2016) CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity 44:913-923
Beharry, Andrew A; Lacoste, Sandrine; O'Connor, Timothy R et al. (2016) Fluorescence Monitoring of the Oxidative Repair of DNA Alkylation Damage by ALKBH3, a Prostate Cancer Marker. J Am Chem Soc 138:3647-50

Showing the most recent 10 out of 88 publications